Emerald BioStructures announced a three-year extension of its ongoing collaboration with UCB.
Almac has established a mass spectrometry laboratory in their European Headquarters, Craigavon, United Kingdom.
Control Company’s Traceable digital hygrometer/thermometer/dew point instrument provides a response time of under 10 seconds with a resolution of 0.01% RH, 0.01°F/°C, and 0.01° dew point °F/°C.
The arium pro from Sartorius Stedim Biotech provides ultrapure water for analytical applications like atomic absorption, ion exchange chromatography and inductively coupled plasma mass spectrometry.
Hamilton Storage Technologies and Robotics have delivered and successfully installed an integrated compound management system at Boehringer Ingelheim's Research and Development Centre.
Activartis GmbH is developing a cancer immunotherapy concept which is currently in Phase 2 clinical trials. The Activartis platform focuses on dendritic cells, the key regulatory elements of the immune system.
Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 17% in the third quarter, chiefly spurred by strong sales of its new diabetes drugs.
Pfizer Inc.'s blockbuster vaccine against dangerous bacterial infections has been approved in Europe for use in adults age 50 and older, the drugmaker announced.
Drug maker AstraZeneca says underlying profit was down 2% in the third quarter but net profit more than doubled because of the sale of a subsidiary.
Bayer AG says its earnings more than doubled in the third quarter compared with a year-earlier figure that was weighed down by one-time charges.
Drugmaker Bristol-Myers Squibb Co. reported a 2% increase in its third-quarter profit, as price increases and higher sales of several key medicines were mostly offset by higher taxes and increased research and marketing costs.
Aspect Imaging’s Certainti software offers a push button approach for preclinical research applications on its M2 MRI system.
Apeptico announced completion of a Phase 1 clinical trial for its pulmonary sodium ion channel activator AP301.
Boehringer Ingelheim’s investigational tyrosine kinase inhibitor BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis.
The National Organization for Rare Disorders released a report documenting flexibility in the Food and Drug Administration review of potential treatments for patients with rare diseases.